体内CAR-T疗法的研究进展与临床应用前景

doi:10.19586/j.2095-2341.2025.0159

生物技术进展 ›› 2026, Vol. 16 ›› Issue (4): 909-918.DOI: 10.19586/j.2095-2341.2025.0159

体内CAR-T疗法的研究进展与临床应用前景

张名笛¹(), 李启垓²(), 王露², 欧阳慧², 练璟华², 谢飞¹()

^1.北京工业大学化学与生命科学学院，北京 100124
^2.广东省惠州中学，广东惠州 516001

收稿日期:2025-11-17 接受日期:2026-01-21 出版日期:2026-07-25 发布日期:2026-09-11
通信作者: 谢飞
作者简介:张名笛 E-mail: 1830678993@qq.com
李启垓 E-mail: qigailee@163.com第一联系人：本文共同第一作者。
基金资助:
军委后勤保障部开放研究重点项目(BHJ17L08)

Research Advances and Clinical Application Prospects of in Vivo CAR-T Therapy

Mingdi ZHANG¹(), Qigai LI²(), Lu WANG², Hui OUYANG², Jinghua LIAN², Fei XIE¹()

^1.College of Chemistry and Life Science，Beijing University of Technology，Beijing 100124，China
^2.Huizhou High School，Guangdong Province，Guangdong Huizhou 516001，China

Received:2025-11-17 Accepted:2026-01-21 Online:2026-07-25 Published:2026-09-11
Contact: Fei XIE

摘要/Abstract

摘要：

嵌合抗原受体T细胞（chimeric antigen receptor T-cell，CAR-T）疗法作为一种革命性的免疫治疗方法，已在血液系统恶性肿瘤治疗中展现出显著的临床效果。然而，传统的体外CAR-T疗法因存在的众多问题，限制了其广泛应用。近年来，直接体内改造T细胞的CAR-T疗法有望克服传统疗法的局限性。综述总结了体内CAR-T疗法的技术原理，及其最新研究进展、临床应用潜力、安全性问题和未来发展方向，旨在为恶性肿瘤临床研究提供全面的参考，并推动这一创新疗法的进一步优化与转化。

关键词: CAR-T疗法, 体内基因编辑, 免疫治疗, 恶性肿瘤, 安全性

Abstract:

Chimeric antigen receptor T-cell （CAR-T） therapy， as a revolutionary immunotherapy method， has demonstrated remarkable clinical efficacy in the treatment of hematological malignancies. However， the traditional in vitro CAR-T therapy is limited in wide application due to numerous problems. In recent years， the research on in vivo CAR-T therapy， which directly modifies T cells in the body， holds the promise of overcoming the limitations of traditional therapies. This article reviewed the technical principles，latest research progress， clinical application potential， safety issues， and future development directions of CAR-T therapy in vivo， aiming to provide comprehensive references for clinical research on malignant tumors and promote the further optimization and transformation of innovative therapy.

Key words: CAR-T therapy, in vivo gene editing, immunotherapy, malignant tumors, safety

中图分类号:

Q291

张名笛, 李启垓, 王露, 欧阳慧, 练璟华, 谢飞. 体内CAR-T疗法的研究进展与临床应用前景[J]. 生物技术进展, 2026, 16(4): 909-918.

Mingdi ZHANG, Qigai LI, Lu WANG, Hui OUYANG, Jinghua LIAN, Fei XIE. Research Advances and Clinical Application Prospects of in Vivo CAR-T Therapy[J]. Current Biotechnology, 2026, 16(4): 909-918.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://swjsjz.magtechjournal.com/CN/10.19586/j.2095-2341.2025.0159

https://swjsjz.magtechjournal.com/CN/Y2026/V16/I4/909

图/表 3

参考文献 67

[1]	ZHAI Y, HE K, HUANG L, et al.. DLK1-directed chimeric antigen receptor T-cell therapy for hepatocellular carcinoma[J]. Liver Int., 2022, 42(11): 2524-2537.
[2]	BUECHNER J, KERSTEN M J, FUCHS M, et al.. Chimeric antigen receptor-T cell therapy: practical considerations for implementation in Europe[J/OL]. HemaSphere, 2018, 2(1): e18[2025-09-25]. .
[3]	LAI M, SHAO W, MAO J, et al.. Revolution in cell therapy: in vivo chimeric-antigen-receptor-T-cell therapy breakthroughs and promises for the future[J/OL]. Res. Wash. D C, 2025, 8: 0917[2025-09-25]. .
[4]	ZUO Y H, ZHAO X P, FAN X X. Nanotechnology-based chimeric antigen receptor T-cell therapy in treating solid tumor[J/OL]. Pharmacol. Res., 2022, 184: 106454[2025-09-25]. .
[5]	ISMAIL F S, GALLUS M, MEUTH S G, et al.. Current and future roles of chimeric antigen receptor T-cell therapy in neurology: a review[J]. JAMA Neurol., 2025, 82(1): 93-103.
[6]	MILLER M A. Nanoparticles improve economic mileage for CARs[J/OL]. Sci. Transl. Med., 2017, 9(387): eaan2784[2025-09-25]. .
[7]	FOSTER J B, BARRETT D M, KARIKÓ K. The emerging role of in vitro-transcribed mRNA in adoptive T cell immunotherapy[J]. Mol. Ther., 2019, 27(4): 747-756.
[8]	TAO R, HAN X, BAI X, et al.. Revolutionizing cancer treatment: enhancing CAR-T cell therapy with CRISPR/Cas9 gene editing technology[J/OL]. Front. Immunol., 2024, 15: 1354825[2025-09-25]. .
[9]	ZAKAS P M, CUNNINGHAM S C, DOHERTY A, et al.. Sleeping Beauty mRNA-LNP enables stable rAAV transgene expression in mouse and NHP hepatocytes and improves vector potency[J]. Mol. Ther., 2024, 32(10): 3356-3371.
[10]	BIMBO J F, VAN DIEST E, MURPHY D E, et al.. T cell-specific non-viral DNA delivery and in vivo CAR-T generation using targeted lipid nanoparticles[J/OL]. J. Immunother. Cancer, 2025, 13(7): e011759[2025-09-25]. .
[11]	YE X, GE M, TAN M, et al.. CD19-targeted CAR T therapy treating hematologic malignancies: hidden danger is the next neighbor to security?[J/OL]. Front. Immunol., 2025, 16: 1490491[2025-09-25]. .
[12]	GENG G, XU Y, HU Z, et al.. Viral and non-viral vectors in gene therapy: current state and clinical perspectives[J/OL]. EBioMedicine, 2025, 118: 105834[2025-09-25]. .
[13]	WANG D, ZHOU Q, QIU X, et al.. Optimizing rAAV6 transduction of primary T cells for the generation of anti-CD19 AAV-CAR-T cells[J/OL]. Biomed. Pharmacother., 2022, 150: 113027[2025-09-25]. .
[14]	ARJOMANDNEJAD M, DASGUPTA I, FLOTTE T R, et al.. Immunogenicity of recombinant adeno-associated virus (AAV) vectors for gene transfer[J]. BioDrugs, 2023, 37(3): 311-329.
[15]	VINK C A, GASPAR H B, GABRIEL R, et al.. Sleeping beauty transposition from nonintegrating lentivirus[J]. Mol. Ther., 2009, 17(7): 1197-1204.
[16]	APOLONIA L, WADDINGTON S N, FERNANDES C, et al.. Stable gene transfer to muscle using non-integrating lentiviral vectors[J]. Mol. Ther., 2007, 15(11): 1947-1954.
[17]	RAUT S D, LEI P, PADMASHALI R M, et al.. Fibrin-mediated lentivirus gene transfer: implications for lentivirus microarrays[J]. J. Control. Release, 2010, 144(2): 213-220.
[18]	GILL S, JUNE C H. Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies[J]. Immunol. Rev., 2015, 263(1): 68-89.
[19]	BUSHMAN F D. Retroviral insertional mutagenesis in humans: evidence for four genetic mechanisms promoting expansion of cell clones[J]. Mol. Ther., 2020, 28(2): 352-356.
[20]	PINTO I S, CORDEIRO R A, FANECA H. Polymer- and lipid-based gene delivery technology for CAR T cell therapy[J]. J. Control. Release, 2023, 353: 196-215.
[21]	NIU H, ZHAO P, SUN W. Biomaterials for chimeric antigen receptor T cell engineering[J]. Acta Biomater., 2023, 166: 1-13.
[22]	HOU X, ZAKS T, LANGER R, et al.. Lipid nanoparticles for mRNA delivery[J]. Nat. Rev. Mater., 2021, 6(12): 1078-1094.
[23]	MALBURET C, LECLERCQ L, COTTE J F, et al.. Size and charge characterization of lipid nanoparticles for mRNA vaccines[J]. Anal. Chem., 2022, 94(11): 4677-4685.
[24]	MÉRIAN J, BOISGARD R, DECLEVES X, et al.. Synthetic lipid nanoparticles targeting steroid organs[J]. J. Nucl. Med., 2013, 54(11): 1996-2003.
[25]	ZHANG J, YANG X, CHANG Z, et al.. Polymeric nanocarriers for therapeutic gene delivery[J/OL]. Asian J. Pharm. Sci., 2025, 20(1): 101015[2025-09-25]. .
[26]	CAI X, DOU R, GUO C, et al.. Cationic polymers as transfection reagents for nucleic acid delivery[J/OL]. Pharmaceutics, 2023, 15(5): 1502[2025-09-25]. .
[27]	HARGUINDEY A, ROY S, HARRIS A W, et al.. Click nucleic acid mediated loading of prodrug activating enzymes in PEG-PLGA nanoparticles for combination chemotherapy[J]. Biomacromolecules, 2019, 20(4): 1683-1690.
[28]	CHAN M S, TAM D Y, DAI Z, et al.. Mitochondrial delivery of therapeutic agents by amphiphilic DNA nanocarriers[J]. Small Weinheim Der Bergstrasse Ger., 2016, 12(6): 770-781.
[29]	GYANANI V, GOSWAMI R. Key design features of lipid nanoparticles and electrostatic charge-based lipid nanoparticle targeting[J/OL]. Pharmaceutics, 2023, 15(4): 1184[2025-09-25]. .
[30]	CHAROENPHOL P, BERMUDEZ H. Design and application of multifunctional DNA nanocarriers for therapeutic delivery[J]. Acta Biomater., 2014, 10(4): 1683-1691.
[31]	VUORIMAA E, URTTI A, SEPPÄNEN R, et al.. Time-resolved fluorescence spectroscopy reveals functional differences of cationic polymer-DNA complexes[J]. J. Am. Chem. Soc., 2008, 130(35): 11695-11700.
[32]	ZHOU J E, SUN L, JIA Y, et al.. Lipid nanoparticles produce chimeric antigen receptor T cells with interleukin-6 knockdown in vivo [J]. J. Control. Release, 2022, 350: 298-307.
[33]	HU Y, ZHOU Y, ZHANG M, et al.. CRISPR/Cas9-engineered universal CD19/CD22 dual-targeted CAR-T cell therapy for relapsed/refractory B-cell acute lymphoblastic leukemia[J]. Clin. Cancer Res., 2021, 27(10): 2764-2772.
[34]	GUO J, TANG Q. Recent updates on chimeric antigen receptor T cell therapy for hepatocellular carcinoma[J]. Cancer Gene Ther., 2021, 28(10-11): 1075-1087.
[35]	BILLINGSLEY M M, SINGH N, RAVIKUMAR P, et al.. Ionizable lipid nanoparticle-mediated mRNA delivery for human CAR T cell engineering[J]. Nano Lett., 2020, 20(3): 1578-1589.
[36]	YANG C H, SHEN K Y, HO H M, et al.. Boosting DNA vaccine power by lipid nanoparticles surface engineered with amphiphilic bioresorbable copolymer[J/OL]. Mol. Ther. Nucleic Acids, 2024, 35(3): 102261[2025-09-25]. .
[37]	QASIM W. Genome-edited allogeneic donor "universal" chimeric antigen receptor T cells[J]. Blood, 2023, 141(8): 835-845.
[38]	LI Y R, ZHU Y, HALLADAY T, et al.. In vivo CAR engineering for immunotherapy[J]. Nat. Rev. Immunol., 2025, 25: 725-744.
[39]	YANG Z, WANG Y. Clinical development of chimeric antigen receptor-T cell therapy for hematological malignancies[J]. Chin. Med. J., 2023, 136(19): 2285-2296.
[40]	DHOLARIA B R, BACHMEIER C A, LOCKE F. Mechanisms and management of chimeric antigen receptor T-cell therapy-related toxicities[J]. BioDrugs, 2019, 33(1): 45-60.
[41]	VO M C, TRAN V D, NGUYEN V T, et al.. Challenges and limitations of chimeric antigen receptor T-cell therapies in solid tumors: why are approvals restricted to hematologic malignancies?[J/OL]. J. Hematol. Oncol., 2025, 18(1): 91[2025-09-25]. .
[42]	LEE M Y, ROBBINS Y, SIEVERS C, et al.. Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells[J/OL]. J. Immunother. Cancer, 2021, 9(3): e002128[2025-09-25]. .
[43]	REPPEL L, TSAHOURIDIS O, AKULIAN J, et al.. Targeting disialoganglioside GD2 with chimeric antigen receptor-redirected T cells in lung cancer[J/OL]. J. Immunother. Cancer, 2022, 10(1): e003897[2025-09-25]. .
[44]	GALANOPOULOS M, DOUKATAS A, GKEROS F, et al.. Room for improvement in the treatment of pancreatic cancer: Novel opportunities from gene targeted therapy[J]. World J. Gastroenterol., 2021, 27(24): 3568-3580.
[45]	CHEN P, XIA Y, LEI W, et al.. Case report: Hashimoto's thyroiditis after CD19 chimeric antigen receptor T-cell therapy[J/OL]. Front. Immunol., 2022, 13: 995496[2025-09-25]. .
[46]	RUELLA M, KENDERIAN S S, SHESTOVA O, et al.. The addition of the BTK inhibitor ibrutinib to anti-CD19 chimeric antigen receptor T cells (CART19) improves responses against mantle cell lymphoma[J]. Clin. Cancer Res., 2016, 22(11): 2684-2696.
[47]	ALCANTARA M, RUSQUEC P D, ROMANO E. Current clinical evidence and potential solutions to increase benefit of CAR T-cell therapy for patients with solid tumors[J/OL]. Oncoimmunology, 2020, 9(1): 1777064[2025-09-25]. .
[48]	ZHANG Y, WANG P, WANG T, et al.. Chimeric antigen receptor T cells engineered to secrete CD40 agonist antibodies enhance antitumor efficacy[J/OL]. J. Transl. Med., 2021, 19(1): 82[2025-09-25]. .
[49]	NIU H, ZHAO P, SUN W. Biomaterials for chimeric antigen receptor T cell engineering[J]. Acta Biomater., 2023, 166: 1-13.
[50]	DU J, LYU X, ZHANG Z, et al.. Revisiting targeted therapy and immunotherapy for advanced cholangiocarcinoma[J/OL]. Front. Immunol., 2023, 14: 1142690[2025-09-25]. .
[51]	LI X, ZHU T, WANG R, et al.. Genetically programmable vesicles for enhancing CAR-T therapy against solid tumors[J/OL]. Adv. Mater., 2023, 35(19): 2211138[2025-09-25]. .
[52]	REN J, ZHAO Y. Advancing chimeric antigen receptor T cell therapy with CRISPR/Cas9[J]. Protein Cell, 2017, 8(9): 634-643.
[53]	DAI Z, MU W, ZHAO Y, et al.. T cells expressing CD5/CD7 bispecific chimeric antigen receptors with fully human heavy-chain-only domains mitigate tumor antigen escape[J/OL]. Signal Transduct. Target. Ther., 2022, 7(1): 85[2025-09-25]. .
[54]	KOTTERMAN M A, CHALBERG T W, SCHAFFER D V. Viral vectors for gene therapy: translational and clinical outlook[J]. Annu. Rev. Biomed. Eng., 2015, 17: 63-89.
[55]	LAM N, TRINKLEIN N D, BUELOW B, et al.. Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains[J/OL]. Nat. Commun., 2020, 11(1): 283[2025-09-25]. .
[56]	TAN A H J, VINANICA N, CAMPANA D. Chimeric antigen receptor-T cells with cytokine neutralizing capacity[J]. Blood Adv., 2020, 4(7): 1419-1431.
[57]	KHANIYA A, RAD S M A H, HALPIN J, et al.. Development of a compact bidirectional promoter-driven dual chimeric antigen receptor (CAR) construct targeting CD19 and CD20 in the Sleeping Beauty (SB) transposon system[J/OL]. J. Immunother. Cancer, 2024, 12(4): e008555[2025-09-25]. .
[58]	GEORGIADIS C, PREECE R, QASIM W. Clinical development of allogeneic chimeric antigen receptor αβ-T cells[J]. Mol. Ther., 2025, 33(6): 2426-2440.
[59]	RURIK J G, TOMBÁCZ I, YADEGARI A, et al.. CAR T cells produced in vivo to treat cardiac injury[J]. Science, 2022, 375(6576): 91-96.
[60]	SRIVASTAVA S, SALTER A I, LIGGITT D, et al.. Logic-gated ROR1 chimeric antigen receptor expression rescues T cell-mediated toxicity to normal tissues and enables selective tumor targeting[J]. Cancer Cell, 2019, 35(3): 489-503.
[61]	DING C, SONG Z, SHEN A, et al.. Small molecules targeting the innate immune cGAS-STING-TBK1 signaling pathway[J]. Acta Pharm. Sin. B, 2020, 10(12): 2272-2298.
[62]	CHEN J, HNATH B, SHA C M, et al.. Optogenetically engineered Septin-7 enhances immune cell infiltration of tumor spheroids[J/OL]. Proc. Natl. Acad. Sci. USA, 2024, 121(44): e2405717121[2025-09-25]. .
[63]	WATKINSON F, NAYAR S K, RANI A, et al.. IL-15 upregulates telomerase expression and potently increases proliferative capacity of NK, NKT-like, and CD8 T cells[J/OL]. Front. Immunol., 2020, 11: 594620[2025-09-25]. .
[64]	BORCHERDING N, BRESTOFF J R. The power and potential of mitochondria transfer[J]. Nature, 2023, 623(7986): 283-291.
[65]	GREEN H N, CROCKETT S D, MARTYSHKIN D V, et al.. A histological evaluation and in vivo assessment of intratumoral near infrared photothermal nanotherapy-induced tumor regression[J]. Int. J. Nanomed., 2014, 9: 5093-5102.
[66]	WANG Y, JIN S, ZHUANG Q, et al.. Chimeric antigen receptor natural killer cells: a promising antitumor immunotherapy[J/OL]. MedComm, 2023, 4(6): e422[2025-09-25]. .
[67]	GAO L, SHI C, YANG Z, et al.. Convection-enhanced delivery of nanoencapsulated gene locoregionally yielding ErbB2/Her2-specific CAR-macrophages for brainstem glioma immunotherapy[J/OL]. J. Nanobiotechnol., 2023, 21(1): 56[2025-09-25]. .

载体类型	核心特性	在体内CAR-T中的优势	局限性
腺相关病毒（AAV）	非致病性、单链DNA、多数无整合能力、血清型特异性靶向（如AAV6靶向T细胞）	安全性高、T细胞靶向性强、表达稳定性好	装载容量有限（约4.7 kb）、免疫原性问题（如预存抗体）
慢病毒（LV）	逆转录病毒科、整合型、感染分裂与非分裂细胞、整合位点随机	长期表达能力强、装载容量较大（约 8 kb）、感染效率高	插入突变风险、生产难度大、免疫原性较强
逆转录病毒（RV）	仅感染分裂期细胞、整合效率高、整合位点偏好转录起始区域	整合效率高、技术成熟度高	细胞周期依赖性强、插入致癌风险高、装载容量有限（约6 kb）

载体类型	核心特性	在体内CAR-T中的优势	局限性
腺相关病毒（AAV）	非致病性、单链DNA、多数无整合能力、血清型特异性靶向（如AAV6靶向T细胞）	安全性高、T细胞靶向性强、表达稳定性好	装载容量有限（约4.7 kb）、免疫原性问题（如预存抗体）
慢病毒（LV）	逆转录病毒科、整合型、感染分裂与非分裂细胞、整合位点随机	长期表达能力强、装载容量较大（约 8 kb）、感染效率高	插入突变风险、生产难度大、免疫原性较强
逆转录病毒（RV）	仅感染分裂期细胞、整合效率高、整合位点偏好转录起始区域	整合效率高、技术成熟度高	细胞周期依赖性强、插入致癌风险高、装载容量有限（约6 kb）

载体类型	核心特性	在体内CAR-T中的优势	局限性
脂质纳米颗粒（LNP）	核-壳结构，包裹mRNA/DNA；通过内吞进入细胞，酸性环境中结构变化实现内体逃逸^[31]	生物相容性好、递送效率较高、技术成熟度高	靶向性有限、表达周期短、规模化生产成本较高
聚合物纳米载体	阳离子聚合物与核酸静电结合；通过内吞进入，部分聚合物可促进内体逃逸^[32]	负载能力强、结构可设计性高、生产成本低	细胞毒性较高、递送效率不稳定、内体逃逸效率低
DNA纳米载体	DNA自组装形成纳米结构，可包裹CAR基因；尺寸可控，生物相容性好	靶向精度高、生物安全性优、功能模块化	制备难度大、体内稳定性差、转染效率低

载体类型	核心特性	在体内CAR-T中的优势	局限性
脂质纳米颗粒（LNP）	核-壳结构，包裹mRNA/DNA；通过内吞进入细胞，酸性环境中结构变化实现内体逃逸^[31]	生物相容性好、递送效率较高、技术成熟度高	靶向性有限、表达周期短、规模化生产成本较高
聚合物纳米载体	阳离子聚合物与核酸静电结合；通过内吞进入，部分聚合物可促进内体逃逸^[32]	负载能力强、结构可设计性高、生产成本低	细胞毒性较高、递送效率不稳定、内体逃逸效率低
DNA纳米载体	DNA自组装形成纳米结构，可包裹CAR基因；尺寸可控，生物相容性好	靶向精度高、生物安全性优、功能模块化	制备难度大、体内稳定性差、转染效率低

	体外CAR-T疗法	体内CAR-T疗法
技术流程	①白细胞分离术抽取患者外周血；②免疫磁珠分选分离T细胞；③GMP实验室病毒/非病毒载体介导CAR基因转染；④细胞因子（IL-2/IL-7）体外扩增（10⁵→10⁹~10¹⁰个）；⑤质量检测（CAR表达率、活性、内毒素）；⑥静脉回输患者体内	①规模化生产携带CAR基因的递送载体（AAV/LNP等）；②载体质量检测（靶向性、基因包封率）；③静脉/局部注射载体至患者体内；④载体体内靶向T细胞并实现CAR基因原位表达与T细胞改造
治疗周期	从抽血到回输需2~4周，T细胞数量不足/功能弱时可延长至6周，其间需桥接治疗控制肿瘤	载体可提前储存，患者确诊后1~2 d完成给药前评估，给药后1~3 d检测到CAR-T活性，总周期≤1周
治疗成本	单例成本30万~50万美元，核心成本：白细胞分离术（≈2万美元）、GMP细胞培养（≈10万美元）、病毒载体制备（≈15万美元）、质量检测（≈5万美元）	单例成本有望降至5 万~10万美元，核心成本：规模化载体生产（LNP：1 000~5 000美元·剂^-1；AAV：1万~3万美元·剂^-1）；无细胞分离/培养成本
T细胞功能特性	体外培养易致T细胞耗竭：PD-1/LAG-3阳性率 60%~80%（新鲜T细胞仅10%~20%）；体内存活时间2~4周；记忆T细胞比例 15%~20%，长期抗肿瘤记忆弱	体内生理环境保留T细胞功能，无明显耗竭标志物高表达；体内存活时间8~12周；记忆T细胞比例35%~45%，可动态改造新生T细胞，维持长期活性^[39]
适用人群	仅30%~40%患者符合标准，排除以下人群：T细胞数量<1×10⁵个·mL^-1（老年/多次化疗患者）；合并严重感染（活动性乙肝）、器官衰竭（肝功能Child-Pugh C级）；无法耐受白细胞分离术	适用人群大幅拓展，可覆盖T细胞数量不足/功能弱的患者；合并轻度器官功能不全/感染的患者；实体瘤患者（肿瘤微环境内直接改造T细胞，减少迁移损耗）
安全性风险	①主要毒性：CRS（3级及以上发生率20%~30%）、ICANS（3级及以上10%~15%）、B细胞耗竭；②毒性管理成熟：CRS用托珠单抗，ICANS用糖皮质激素，B细胞耗竭用免疫球蛋白^[40]；③死亡率<1%	①新型风险：载体脱靶感染（肝细胞/红细胞，致肝损伤等）；基因编辑脱靶（潜在二次肿瘤风险）；CAR-T活性难调控（可能引发过度炎症）；②临床前数据：诱导CRS和CAR-T相关脑病综合征（神经毒性），长期安全性待验证^[41]
技术成熟度	已实现临床转化，全球多款产品获批（如阿基仑赛、瑞基奥仑赛），临床数据丰富，质控标准明确	处于临床前/早期临床试验阶段，无获批产品，核心技术（载体靶向性、表达效率）仍需优化，长期疗效与安全性数据不足

体内CAR-T疗法的研究进展与临床应用前景

Research Advances and Clinical Application Prospects of in Vivo CAR-T Therapy

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

图/表 3

参考文献 67

相关文章 15

编辑推荐

Metrics

本文评价

[1]	刘晓霖, 王琪慧. 铁死亡基因NCOA4的表达水平与结肠癌预后和疗效的关系研究[J]. 生物技术进展, 2026, 16(1): 178-189.
[2]	翟晓艺, 刁钟琪, 陈异, 郭文佳. 基于单细胞RNA-seq和批量RNA-seq数据构建乳腺癌患者的肿瘤相关成纤维细胞和相关预后特征的风险模型[J]. 生物技术进展, 2025, 15(6): 1094-1107.
[3]	边裕钦, 董柯然, 卢俊孜, 钟恩鸣, 谷婉莹, 赵靖舒, 隋宏书. 乳腺癌靶向及免疫治疗的临床进展[J]. 生物技术进展, 2025, 15(2): 234-240.
[4]	曾艳, 祝恒成, 杨康. 脱氧核糖核酸酶1在肾细胞癌中的作用及机制研究[J]. 生物技术进展, 2024, 14(3): 486-491.
[5]	余萍, 赵迪, 陈雪娇, 宋佳, 汪海涛, 闵祥博. 罗伊氏粘液乳杆菌HCS02-001缓解高尿酸血症及痛风功能的研究[J]. 生物技术进展, 2024, 14(3): 473-479.
[6]	张永红, 李岩异, 张卫婷. 整合位点分析技术的研究进展[J]. 生物技术进展, 2024, 14(1): 66-71.
[7]	高应瑞, 康福忠, 孟铁健, 刘珂飞, 王调调, 陈金艳, 孙彤. 基于全基因组测序的丁酸梭菌安全性评价[J]. 生物技术进展, 2023, 13(5): 755-759.
[8]	刘婷婷, 仝涛, 黄昆仑. 转基因玉米的研究进展和食用安全性评价[J]. 生物技术进展, 2022, 12(4): 523-531.
[9]	彭灿灿, 王惠明. 适合免疫治疗的大鼠抗肾小球基底膜肾炎模型的建立[J]. 生物技术进展, 2022, 12(3): 473-478.
[10]	李书翔, 安丽萍, 梁德娟, 王凯旋, 赵建国. 朊病毒病治疗方法的研究进展[J]. 生物技术进展, 2022, 12(2): 229-235.
[11]	张凤, 贺晓云, 黄昆仑, 汪其怀. 转基因耐除草剂大豆的食用安全评价研究进展[J]. 生物技术进展, 2021, 11(4): 489-495.
[12]	刘梦昱,谢飞,张鑫,赵鹏翔,. 胶质母细胞瘤免疫治疗研究进展[J]. 生物技术进展, 2019, 9(3): 223-230.
[13]	余艺,万晨露,廖玉霞,贺震旦,李颖. 功能化介孔二氧化硅纳米粒子在恶性肿瘤诊疗中的应用进展[J]. 生物技术进展, 2018, 8(2): 118-123.
[14]	李耿,刘晓志,王志明,高健. 双特异性抗体药物应用进展[J]. 生物技术进展, 2015, 5(6): 420-424.
[15]	于艳琴,杜京旗,赵君,杨卫民. 枣皮红色素理化性质及其食品添加剂研制[J]. 生物技术进展, 2014, 4(2): 129-134.